



“ Cerba Research, your partner in addressing the global COVID-19 pandemic

Testing for your trials

In light of the global COVID-19 (SARS-Cov-2) pandemic, the search for a treatment or vaccine has become urgent and critical. Cerba Research, together with all its partners, is widely using COVID-19 diagnostic tests to detect the virus in patients. In addition, we are assisting in making testing available in clinical trials globally.

Please, feel free to reach out to us if our COVID-19 capabilities and overall understanding of coronavirus pathogenesis can help advance the development of your treatment.

Alternative NGS testing

Next to RT-PCR, we can also provide an NGS test alternative together with our partner, Fulgent, which overcomes the high false negative rate.

The advantages of this test are:

- for symptomatic patients with previous negative results
- understanding patient prognosis
- assessing the association of virus mutations and effectiveness of treatments
- study of virus epidemic evolution

RT-PCR tests available in our partner labs worldwide

RT-PCR tests for COVID-19 are available in our partner labs worldwide.

The standard **TAT is 48 to 72 hours** upon receipt of samples, and the specimen is collected through **nose and throat swabs**.

Precautions biosafety level 2.

Roche (LightMix Modular Assays)

Available in **South Africa, China, Japan, Australia**

Genfinder (CE IVD)

Available in **Europe**

CDC assay

Available in **USA**

GenMark e-Plex

Available in **USA**

Hologic assay

Available in **USA**

.....
The FDA followed Roche's authorization with emergency green lights for tests from Thermo Fisher, Hologic and LabCorp.